肺炎支原体肺炎患儿免疫功能变化及匹多莫德的治疗效果分析

目的：探讨肺炎支原体肺炎（MPP）患儿免疫功能的变化及匹多莫德对其治疗效果。方法：选取MPP患儿54例为MPP组，另选健康儿童54例为正常对照组，检测两组体液及细胞免疫功能指标，并进行对比分析。将MPP组随机分为普通治疗组（给予阿奇霉素治疗）与匹多莫德组（在阿奇霉素基础上加用匹多莫德治疗），对比两组疗效及治疗前后免疫功能指标。结果：MPP组血清IgG、IgM、CD8＋、CD19＋高于正常对照组，而CD3＋、CD4＋、CD4＋／CD8＋、CD16＋CD56＋均低于正常对照组，差异均具有统计学意义（P〈0．01或P〈0．05）；经治疗，54例MPP患儿有效率均为100％，均未发生严重不良反应；匹多莫德组IgA、IgG、IgM未见显著变化，差异无统计学意义（P〉0．05），而CD3＋、CD4＋、CD4＋／CD8＋均较治疗前增高，而CD16＋CD56＋则降低，差异均具有统计学意义（P％0．01），但普通治疗组治疗前后各项免疫指标均未见明显变化（P〉0．05）。结论：MPP患儿可因肺炎支原体的黏附及毒性代谢产物等导致免疫功能障碍，但在常规治疗基础上加用匹多莫德，能够显著改善患儿免疫功能，利于疾病恢复。

Changes of immune function in children with Mycoplasma pneumoniae pneumonia and effects of pidotimod on the disease

Objective： To observe changes of immune function in children with Mycoplasma pneu- moniae pneumonia （MPP） and clinical effects of pidotimod on the disease. Methods： A total of 54 children with MPP were enrolled as MPP group, and 54 healthy volunteers were selected as the healthy control group, IgA, IgG, IgM, CD3＋, CD4＋, CD8＋, CD4＋/CD8＋, CD19＋, and CD16＋, and CD56＋ were de- tected in both groups. Then MPP were randomly subdivided into the conventional therapy group （n=27）and the pidotimod treatment group （n=27）, which were treated with azithromycin or azithromycin ＋ pi- dotimod, respectively. Therapeutic effects and immune function parameters were compared between the two groups. Results. IgG, IgM, CD8＋ , and CD19＋ of the MPP group were significantly higher than that of the healthy control group （P~0.01）, but CD3＋ , CD4＋ , CD4＋/CD8＋ , and CD16＋ , CD56＋ were sig- nificantly lower than the healthy control group （P〈0.01 or P〈0.05）. After the treatment, the effective rate of 54 children with MPP was 100%, and there was no serious adverse reactions observed; no signifi- cant difference in IgA, IgG, IgM was observed in the pidotimod group after the treatment （P）0.05）, but CD3＋ , CD4＋ , and CD4＋/CD8＋ were significantly elevated after treatment （P〈0.01）, CD16＋ , CD56＋ were significantly lower than that before treatment （P〈0.01） but there was no significantly changes of the immune function parameters observed in the conventional therapy group （P〉0.05）. Conclusion： MP infection can lead to immune dysfunction in children with MPP due to toxic product of metabolism, but the use of pidotimod based on the conventional treatment can significantly improve the immune function, and is conducive to the disease recovery.